Horiba MN, Casak SJ, Mishra-Kalyani PS, Roy P, et al. FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease. Clin Cancer Res 2022;28:5244-5248.
PMID: 35960160